ForeseeHome demonstrates a substantial benefit for patients' vision as shown in a real-world retrospective study published last year.
The real-world data analysis of 3.2 million tests performed by 8,991 patients showed that the use of ForeseeHome provided a significant benefit to patients by helping to detect their wet AMD earlier with better visual acuity,1 a factor shown to improve long-term visual outcomes of anti-VEGF treatment.2
The retrospective analysis of medical records from the Notal Vision Monitoring Center identified 306 eyes that converted to wet AMD between October 2009 and September 2018. Functional vision (20/40 or better) at conversion was maintained in 81% of patients in the real-world ForeseeHome cohort compared to only 34% in the American Academy of Ophthalmology's IRIS® Registry real-world data using standard of care.2
Read the Data Analysis
References
- Ho AC, Heier JS, Holekamp N et al. Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration, J. Clin. Med. 2021, 10,1355.
- Ho AC, Kleinman DM, Lum FC, et al. Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes: An Analysis of the IRIS Registry, Ophthalmic Surg Lasers Imaging Retina. 2020;51:633-639.
